Volagidemab
Based on 1 Customer Validation
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: ≥99.0%
- CAS No.: 1233956-13-2
- Masse moléculaire:147.02 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Human IgG2 kappa
Human
GCGR
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Alloxan-induced diabetic mice [2]
-
Dosage:5 mg/kg
-
Administration:Subcutaneous injection (s.c.)
-
Result:Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1233956-13-2
-
Appearance Liquid
-
Masse moléculaire 147.02 kDa
-
Color Colorless to light yellow
-
SMILES
[Volagidemab]
-
Synonyms
REMD-477; AMG-477
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 Oct;28(10):2092-2099. [Content Brief]
[2]. Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2503-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)